{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:10:33Z","timestamp":1793801433227,"version":"4.6.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s00277-023-05474-1","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T16:02:28Z","timestamp":1699632148000},"page":"285-296","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Outcomes of allogeneic hematopoietic cell transplantation under letermovir prophylaxis for cytomegalovirus infection"],"prefix":"10.1007","volume":"103","author":[{"given":"Katsuto","family":"Takenaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Fuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahide","family":"Ara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Ikegame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiyasu","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohisa","family":"Nakamae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keitaro","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Nakasone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,10]]},"reference":[{"issue":"1","key":"5474_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.bbmt.2014.11.002","volume":"21","author":"M Boeckh","year":"2015","unstructured":"Boeckh M, Murphy WJ, Peggs KS (2015) Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies. Biol Blood Marrow Transplant 21(1):24\u201329. https:\/\/doi.org\/10.1016\/j.bbmt.2014.11.002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"5474_CR2","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.1182\/blood-2008-10-143560","volume":"113","author":"M Boeckh","year":"2009","unstructured":"Boeckh M, Ljungman P (2009) How I treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 113(23):5711\u20135719","journal-title":"Blood"},{"issue":"2","key":"5474_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.idc.2010.01.008","volume":"24","author":"P Ljungman","year":"2010","unstructured":"Ljungman P, Hakki M, Boeckh M (2010) Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect Dis Clin N Am 24(2):319\u2013337","journal-title":"Infect Dis Clin N Am"},{"key":"5474_CR4","doi-asserted-by":"publisher","unstructured":"Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, Hubacek P, Navarro D, Cordonnier C, Ward KN  European Conference on Infections in Leukaemia g (2019) Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis 19(8):e260\u2013e272. https:\/\/doi.org\/10.1016\/S1473-3099(19)30107-0","DOI":"10.1016\/S1473-3099(19)30107-0"},{"issue":"4","key":"5474_CR5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","volume":"11","author":"FM Marty","year":"2011","unstructured":"Marty FM, Ljungman P, Papanicolaou GA, Winston DJ, Chemaly RF, Strasfeld L, Young JA, Rodriguez T, Maertens J, Schmitt M, Einsele H, Ferrant A, Lipton JH, Villano SA, Chen H, Boeckh M (2011) Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 11(4):284\u2013292. https:\/\/doi.org\/10.1016\/S1473-3099(11)70024-X","journal-title":"Lancet Infect Dis"},{"issue":"25","key":"5474_CR6","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","volume":"377","author":"FM Marty","year":"2017","unstructured":"Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, Haider S, Ullmann AJ, Katayama Y, Brown J, Mullane KM, Boeckh M, Blumberg EA, Einsele H, Snydman DR, Kanda Y, DiNubile MJ, Teal VL, Wan H et al (2017) Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med 377(25):2433\u20132444. https:\/\/doi.org\/10.1056\/NEJMoa1706640","journal-title":"N Engl J Med"},{"issue":"3","key":"5474_CR7","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/s2352-3026(15)00289-6","volume":"3","author":"ML Green","year":"2016","unstructured":"Green ML, Leisenring W, Xie H, Mast TC, Cui Y, Sandmaier BM, Sorror ML, Goyal S, \u00d6zk\u00f6k S, Yi J, Sahoo F, Kimball LE, Jerome KR, Marks MA, Boeckh M (2016) Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol 3(3):e119\u2013e127. https:\/\/doi.org\/10.1016\/s2352-3026(15)00289-6","journal-title":"Lancet Haematol"},{"issue":"11","key":"5474_CR8","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/j.bbmt.2015.07.019","volume":"21","author":"K Takenaka","year":"2015","unstructured":"Takenaka K, Nishida T, Asano-Mori Y, Oshima K, Ohashi K, Mori T, Kanamori H, Miyamura K, Kato C, Kobayashi N, Uchida N, Nakamae H, Ichinohe T, Morishima Y, Suzuki R, Yamaguchi T, Fukuda T (2015) Cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation is associated with a reduced risk of relapse in patients with acute myeloid leukemia who survived to day 100 after transplantation: the Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group. Biol Blood Marrow Transplant 21(11):2008\u20132016. https:\/\/doi.org\/10.1016\/j.bbmt.2015.07.019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"5474_CR9","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","volume":"127","author":"P Teira","year":"2016","unstructured":"Teira P, Battiwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, Green JS, Saad A, Antin JH, Savani BN, Lazarus HM, Seftel M, Saber W, Marks D, Aljurf M, Norkin M, Wingard JR, Lindemans CA, Boeckh M et al (2016) Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood 127(20):2427\u20132438. https:\/\/doi.org\/10.1182\/blood-2015-11-679639","journal-title":"Blood"},{"issue":"9","key":"5474_CR10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.jtct.2021.05.001","volume":"27","author":"M Hakki","year":"2021","unstructured":"Hakki M, Aitken SL, Danziger-Isakov L, Michaels MG, Carpenter PA, Chemaly RF, Papanicolaou GA, Boeckh M, Marty FM (2021) American Society for Transplantation and Cellular Therapy Series: #3-prevention of cytomegalovirus infection and disease after hematopoietic cell transplantation. Transplant Cell Ther 27(9):707\u2013719. https:\/\/doi.org\/10.1016\/j.jtct.2021.05.001","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"5474_CR11","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.jiac.2022.05.019","volume":"28","author":"H Yoshimura","year":"2022","unstructured":"Yoshimura H, Satake A, Ishii Y, Ichikawa J, Saito R, Konishi A, Hotta M, Nakanishi T, Fujita S, Ito T, Ishii K, Nomura S (2022) Real-world efficacy of letermovir prophylaxis for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation: a single-center retrospective analysis. J Infect Chemother 28(9):1317\u20131323. https:\/\/doi.org\/10.1016\/j.jiac.2022.05.019","journal-title":"J Infect Chemother"},{"issue":"8","key":"5474_CR12","doi-asserted-by":"publisher","first-page":"510.e511","DOI":"10.1016\/j.jtct.2022.05.020","volume":"28","author":"LW Liu","year":"2022","unstructured":"Liu LW, Yn A, Gao F, Olson M, Crain M, Abboud R, Westervelt P, Abboud C, Vij R, Stockerl-Goldstein K, Pusic I, Cashen AF, Schroeder MA (2022) Letermovir discontinuation at day 100 after allogeneic stem cell transplant is associated with increased CMV-related mortality. Transplant Cell Ther 28(8):510.e511\u2013510.e519. https:\/\/doi.org\/10.1016\/j.jtct.2022.05.020","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"5474_CR13","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1080\/10428194.2022.2042686","volume":"63","author":"CW Freyer","year":"2022","unstructured":"Freyer CW, Carulli A, Gier S, Ganetsky A, Timlin C, Schuster M, Babushok D, Frey NV, Gill SI, Hexner EO, Luger SM, Mangan JK, Martin ME, McCurdy SR, Perl AE, Porter DL, Pratz K, Smith J, Stadtmauer EA, Loren AW (2022) Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide. Leuk Lymphoma 63(8):1925\u20131933. https:\/\/doi.org\/10.1080\/10428194.2022.2042686","journal-title":"Leuk Lymphoma"},{"key":"5474_CR14","doi-asserted-by":"publisher","first-page":"874117","DOI":"10.3389\/fonc.2022.874117","volume":"12","author":"M Malagola","year":"2022","unstructured":"Malagola M, Turra A, Signorini L, Corbellini S, Polverelli N, Masina L, Del Fabro G, Lorenzotti S, Fumarola B, Farina M, Morello E, Radici V, Buttini EA, Colnaghi F, Bernardi S, Re F, Caruso A, Castelli F, Russo D (2022) Results of an innovative program for surveillance, prophylaxis, and treatment of infectious complications following allogeneic stem cell transplantation in hematological malignancies (BATMO Protocol). Front Oncol 12:874117. https:\/\/doi.org\/10.3389\/fonc.2022.874117","journal-title":"Front Oncol"},{"issue":"2","key":"5474_CR15","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1182\/bloodadvances.2021005885","volume":"6","author":"Y Akahoshi","year":"2022","unstructured":"Akahoshi Y, Kimura SI, Tada Y, Matsukawa T, Tamaki M, Doki N, Uchida N, Tanaka M, Nakamae H, Kuriyama T, Matsuoka KI, Ikeda T, Kimura T, Fukuda T, Kanda Y, Atsuta Y, Murata M, Terakura S, Nakasone H (2022) Cytomegalovirus gastroenteritis in patients with acute graft-versus-host disease. Blood Adv 6(2):574\u2013584. https:\/\/doi.org\/10.1182\/bloodadvances.2021005885","journal-title":"Blood Adv"},{"key":"5474_CR16","doi-asserted-by":"publisher","unstructured":"Wolfe D, Zhao Q, Siegel E, Puto M, Murphy D, Roddy J, Efebera Y, Tossey J (2021) Letermovir prophylaxis and cytomegalovirus reactivation in adult hematopoietic cell transplant recipients with and without acute graft versus host disease. Cancers (Basel) 13(21). https:\/\/doi.org\/10.3390\/cancers13215572","DOI":"10.3390\/cancers13215572"},{"issue":"16","key":"5474_CR17","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1182\/bloodadvances.2021004362","volume":"5","author":"JA Hill","year":"2021","unstructured":"Hill JA, Zamora D, Xie H, Thur LA, Delaney C, Dahlberg A, Pergam SA, Leisenring WM, Boeckh M, Milano F (2021) Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients. Blood Adv 5(16):3113\u20133119. https:\/\/doi.org\/10.1182\/bloodadvances.2021004362","journal-title":"Blood Adv"},{"issue":"8","key":"5474_CR18","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1007\/s00277-020-04362-2","volume":"100","author":"P Derigs","year":"2021","unstructured":"Derigs P, Radujkovic A, Schubert ML, Schnitzler P, Sch\u00f6ning T, M\u00fcller-Tidow C, Hegenbart U, Sch\u00f6nland SO, Luft T, Dreger P, Schmitt M (2021) Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data. Ann Hematol 100(8):2087\u20132093. https:\/\/doi.org\/10.1007\/s00277-020-04362-2","journal-title":"Ann Hematol"},{"issue":"1","key":"5474_CR19","first-page":"102","volume":"29","author":"B Serio","year":"2021","unstructured":"Serio B, Giudice V, Guariglia R, Fontana R, Pezzullo L, Martorelli MC, Ferrara I, Mettivier L, D\u2019Addona M, Vaccaro E, Langella M, Selleri C (2021) Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study. Infez Med 29(1):102\u2013113","journal-title":"Infez Med"},{"issue":"1","key":"5474_CR20","doi-asserted-by":"publisher","first-page":"85.e81","DOI":"10.1016\/j.bbmt.2020.10.009","volume":"27","author":"A Lin","year":"2021","unstructured":"Lin A, Flynn J, DeRespiris L, Figgins B, Griffin M, Lau C, Proli A, Devlin SM, Cho C, Tamari R, Jakubowski AA, Papadopoulos EB, Giralt SA, Perales MA, Seo SK, Shaffer B (2021) Letermovir for prevention of cytomegalovirus reactivation in haploidentical and mismatched adult donor allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis. Transplant Cell Ther 27(1):85.e81\u201385.e86. https:\/\/doi.org\/10.1016\/j.bbmt.2020.10.009","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"5474_CR21","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1016\/j.bbmt.2020.07.002","volume":"26","author":"JJ Johnsrud","year":"2020","unstructured":"Johnsrud JJ, Nguyen IT, Domingo W, Narasimhan B, Efron B, Brown JW (2020) Letermovir prophylaxis decreases burden of cytomegalovirus (CMV) in patients at high risk for CMV disease following hematopoietic cell transplant. Biol Blood Marrow Transplant 26(10):1963\u20131970. https:\/\/doi.org\/10.1016\/j.bbmt.2020.07.002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"5474_CR22","doi-asserted-by":"publisher","first-page":"e13866","DOI":"10.1111\/ctr.13866","volume":"34","author":"A Anderson","year":"2020","unstructured":"Anderson A, Raja M, Vazquez N, Morris M, Komanduri K, Camargo J (2020) Clinical \u201creal-world\u201d experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients. Clin Transpl 34(7):e13866. https:\/\/doi.org\/10.1111\/ctr.13866","journal-title":"Clin Transpl"},{"issue":"4","key":"5474_CR23","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41409-019-0730-y","volume":"55","author":"P Sharma","year":"2020","unstructured":"Sharma P, Gakhar N, MacDonald J, Abidi MZ, Benamu E, Bajrovic V, Purev E, Haverkos BM, Tobin J, Kaiser J, Chase S, Miller M, Weinberg A, Gutman JA (2020) Letermovir prophylaxis through day 100 post transplant is safe and effective compared with alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantation. Bone Marrow Transplant 55(4):780\u2013786. https:\/\/doi.org\/10.1038\/s41409-019-0730-y","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"5474_CR24","doi-asserted-by":"publisher","first-page":"ofac687","DOI":"10.1093\/ofid\/ofac687","volume":"10","author":"A Vyas","year":"2023","unstructured":"Vyas A, Raval AD, Kamat S, LaPlante K, Tang Y, Chemaly RF (2023) Real-world outcomes associated with letermovir use for cytomegalovirus primary prophylaxis in allogeneic hematopoietic cell transplant recipients: a systematic review and meta-analysis of observational studies. Open Forum Infect Dis 10(1):ofac687. https:\/\/doi.org\/10.1093\/ofid\/ofac687","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"5474_CR25","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/s41409-020-01082-z","volume":"56","author":"Y Mori","year":"2021","unstructured":"Mori Y, Jinnouchi F, Takenaka K, Aoki T, Kuriyama T, Kadowaki M, Odawara J, Ueno T, Kohno K, Harada T, Yoshimoto G, Takase K, Henzan H, Kato K, Ito Y, Kamimura T, Ohno Y, Ogawa R, Eto T et al (2021) Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data. Bone Marrow Transplant 56(4):853\u2013862. https:\/\/doi.org\/10.1038\/s41409-020-01082-z","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"5474_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","volume":"103","author":"Y Atsuta","year":"2016","unstructured":"Atsuta Y (2016) Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol 103(1):3\u201310. https:\/\/doi.org\/10.1007\/s12185-015-1894-x","journal-title":"Int J Hematol"},{"issue":"12","key":"5474_CR27","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD et al (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow. Transplantation 11(12):945\u2013956. https:\/\/doi.org\/10.1016\/j.bbmt.2005.09.004","journal-title":"Transplantation"},{"issue":"8","key":"5474_CR28","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912\u20132919. https:\/\/doi.org\/10.1182\/blood-2005-05-2004","journal-title":"Blood"},{"issue":"8","key":"5474_CR29","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/cid\/ciz490","volume":"70","author":"P Ljungman","year":"2020","unstructured":"Ljungman P, Schmitt M, Marty FM, Maertens J, Chemaly RF, Kartsonis NA, Butterton JR, Wan H, Teal VL, Sarratt K, Murata Y, Leavitt RY, Badshah C (2020) A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation. Clin Infect Dis 70(8):1525\u20131533. https:\/\/doi.org\/10.1093\/cid\/ciz490","journal-title":"Clin Infect Dis"},{"issue":"8","key":"5474_CR30","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1086\/339329","volume":"34","author":"P Ljungman","year":"2002","unstructured":"Ljungman P, Griffiths P, Paya C (2002) Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34(8):1094\u20131097","journal-title":"Clin Infect Dis"},{"key":"5474_CR31","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ (1988) A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141\u20131154","journal-title":"Ann Stat"},{"key":"5474_CR32","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ (1999) A proportional hazards model for subdistribution of a competing risk. J Am Stat Assoc 94:456\u2013509","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"5474_CR33","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48(3):452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"5474_CR34","doi-asserted-by":"publisher","first-page":"534268","DOI":"10.3389\/fcell.2020.534268","volume":"8","author":"M Malagola","year":"2020","unstructured":"Malagola M, Pollara C, Polverelli N, Zollner T, Bettoni D, Gandolfi L, Gramegna D, Morello E, Turra A, Corbellini S, Signorini L, Moioli G, Bernardi S, Zanaglio C, Farina M, Testa TE, Caruso A, Russo D (2020) Advances in CMV management: a single center real-life experience. Front Cell Dev Biol 8:534268. https:\/\/doi.org\/10.3389\/fcell.2020.534268","journal-title":"Front Cell Dev Biol"},{"key":"5474_CR35","doi-asserted-by":"publisher","unstructured":"Royston L, Royston E, Masouridi-Levrat S, Vernaz N, Chalandon Y, Van Delden C, Neofytos D (2021) Letermovir primary prophylaxis in high-risk hematopoietic cell transplant recipients: a matched cohort study. Vaccines (Basel) 9(4). https:\/\/doi.org\/10.3390\/vaccines9040372","DOI":"10.3390\/vaccines9040372"},{"issue":"3","key":"5474_CR36","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/iid3.431","volume":"9","author":"L Royston","year":"2021","unstructured":"Royston L, Royston E, Masouridi-Levrat S, Chalandon Y, Van Delden C, Neofytos D (2021) Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high-risk hematopoietic cell transplant recipients. Immun Inflamm Dis 9(3):771\u2013776. https:\/\/doi.org\/10.1002\/iid3.431","journal-title":"Immun Inflamm Dis"},{"issue":"8","key":"5474_CR37","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/cid\/ciab298","volume":"73","author":"J Sassine","year":"2021","unstructured":"Sassine J, Khawaja F, Shigle TL, Handy V, Foolad F, Aitken SL, Jiang Y, Champlin R, Shpall E, Rezvani K, Ariza-Heredia EJ, Chemaly RF (2021) Refractory and resistant cytomegalovirus after hematopoietic cell transplant in the letermovir primary prophylaxis era. Clin Infect Dis 73(8):1346\u20131354. https:\/\/doi.org\/10.1093\/cid\/ciab298","journal-title":"Clin Infect Dis"},{"issue":"4","key":"5474_CR38","doi-asserted-by":"publisher","first-page":"211.e211","DOI":"10.1016\/j.jtct.2022.01.008","volume":"28","author":"E Gabanti","year":"2022","unstructured":"Gabanti E, Borsani O, Colombo AA, Zavaglio F, Binaschi L, Caldera D, Sciarra R, Cassinelli G, Alessandrino EP, Bernasconi P, Ferretti VV, Lilleri D, Baldanti F (2022) Human cytomegalovirus-specific T-cell reconstitution and late-onset cytomegalovirus infection in hematopoietic stem cell transplantation recipients following letermovir prophylaxis. Transplant Cell Ther 28(4):211.e211\u2013211.e219. https:\/\/doi.org\/10.1016\/j.jtct.2022.01.008","journal-title":"Transplant Cell Ther"},{"key":"5474_CR39","doi-asserted-by":"publisher","unstructured":"Dadwal S, Russo D, Stelljes M, Schmitt M, Pilorge S, Teal V, Haber B, Bopp C, Badshah C (2023) A phase 3 randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of letermovir (LET) prophylaxis when extended from 100 to 200 days post-transplant in cytomegalovirus (CMV)-seropositive recipients (R+) of an allogeneic hematopoietic stem cell transplant (HSCT). Transplant Cell Ther 29(2, supplement):S64 (meeting abstract). https:\/\/doi.org\/10.1016\/S2666-6367(23)00145-8","DOI":"10.1016\/S2666-6367(23)00145-8"},{"issue":"1","key":"5474_CR40","doi-asserted-by":"publisher","first-page":"e2016031","DOI":"10.4084\/MJHID.2016.031","volume":"8","author":"R de la Camara","year":"2016","unstructured":"de la Camara R (2016) CMV in hematopoietic stem cell transplantation. Mediterr J Hematol Infect Dis 8(1):e2016031. https:\/\/doi.org\/10.4084\/MJHID.2016.031","journal-title":"Mediterr J Hematol Infect Dis"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05474-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05474-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05474-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T18:05:47Z","timestamp":1704218747000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05474-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,10]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["5474"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05474-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,10]]},"assertion":[{"value":"21 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the data management committee of the JSTCT and by the ethics committee of the Ehime University School of Medicine. All procedures performed in studies were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"K.T. has received a speaker honoraria from MSD, outside the submitted work. Other authors declare no competing financial interests regarding this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}